Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

The locus coeruleus (LC), the major noradrenergic nucleus of the brain, gives rise to fibres innervating most structures of the neuraxis. Recent advances in neuroscience have helped to unravel the neuronal circuitry controlling a number of physiological functions in which the LC plays a central role. Two such functions are the regulation of arousal and autonomic activity, which are inseparably linked largely via the involvement of the LC. Alterations in LC activity due to physiological or pharmacological manipulations or pathological processes can lead to distinct patterns of change in arousal and autonomic function. Physiological manipulations considered here include the presentation of noxious or anxiety-provoking stimuli and extremes in ambient temperature. The modification of LC-controlled functions by drug administration is discussed in detail, including drugs which directly modify the activity of LC neurones (e.g., via autoreceptors, storage, reuptake) or have an indirect effect through modulating excitatory or inhibitory inputs. The early vulnerability of the LC to the ageing process and to neurodegenerative disease (Parkinson's and Alzheimer's diseases) is of considerable clinical significance. In general, physiological manipulations and the administration of stimulant drugs, alpha(2)-adrenoceptor antagonists and noradrenaline uptake inhibitors increase LC activity and thus cause heightened arousal and activation of the sympathetic nervous system. In contrast, the administration of sedative drugs, including alpha(2)-adrenoceptor agonists, and pathological changes in LC function in neurodegenerative disorders and ageing reduce LC activity and result in sedation and activation of the parasympathetic nervous system.

BRIEF OUTLINE OF THE ROLE OF THE LOCUS COERULEUS IN THE MAINTENANCE OF AROUSAL AND REGULATION OF AUTONOMIC FUNCTIONS

The LC, the largest group of noradrenergic neurones in the central nervous system, is a major nucleus involved in the neural pathways controlling arousal and autonomic function. These physiological functions are inseparably linked, largely due to the central role of the LC in controlling these functions. The LC projects extensively to widespread areas of the neuraxis (see Part I) and these projections can result in both excitatory effects via the activation of α1-adrenoceptors and inhibitory effects via the stimulation of α2-adrenoceptors [206]. Therefore, complex changes in the neural circuitry underlying arousal and autonomic function result from changes in LC activity.

Arousal

The LC is recognised as a major wakefulness-promoting nucleus [304, 305], where the activity of the LC closely correlates with level of arousal [16, 17, 18, 122, 123, 355, 360]. This wakefulness-promoting action results from the dense projections from the LC to most areas of the cerebral cortex [208] and from the multitude of projections from the LC to alertness-modulating nuclei (see Part I). The LC exerts an excitatory influence on wakefulness-promoting neurones such as cholinergic neurones of the BF [111, 126, 203, 205] and of the PPT and LDT nuclei [26], cortically-projecting neurones of the thalamus [280, 281] and serotonergic neurones of the DR [219, 309, 375], and an inhibitory influence on sleep-promoting GABA-ergic neurones of the BF [268, 288, 451] and VLPO of the hypothalamus [74, 288, 319]. Thus, increases in LC activity result in increases in EEG signs of alertness [29] whilst inactivation of the LC reduces this EEG activity [30, 91], demonstrating a reduction in alertness. Furthermore, the LC exerts a powerful inhibitory influence on REM sleep, probably by inhibiting a subgroup of cholinergic neurones in the pedunculopontine tegmental nucleus involved in REM sleep [185] (see Part I). Indeed, electrical stimulation of the LC has been found to reduce the quantity of SWS and REM sleep in a human subject [211], demonstrating an increase in wakefulness. A schematic diagram outlining the sleep/arosal neuronal network, highlighting the central position of the LC, is shown in Fig. ().

Autonomic Functions

It is also well recognised that the LC plays an important role in controlling autonomic functions (see Part I). As a major premotor autonomic nucleus, the LC sends direct projections to the sympathetic preganglionic neurones in the spinal cord [208, 316, 489] and parasympathetic preganglionic neurones in the brainstem and spinal cord (EWN: [50, 255]; salivatory nuclei: [203, 419]; DMV: [309, 457, 490]; nucleus ambiguus: [208, 490]; spinal cord: [208, 385, 490, 506]). It should be noted that the DMV also contains somatomotor neurones to varying degrees in different mammalian species [256], and in fact in humans it is almost completely somatmotor. [52]. On the other hand, the EWN is an almost exclusively preganglonic parasympathetic nucleus in man [52]. In general, the LC increases sympathetic activity via the activation of α1-adrenoceptors on preganglionic sympathetic neurones [248] and reduces parasympathetic activity via the activation of α2-adrenoceptors on preganglionic parasympathetic neurones [418, 465, 501]. Furthermore, the LC also exerts an indirect effect on autonomic activity via projections to other premotor autonomic nuclei such as the PVN [207, 208, 309, 440, 461], the RVLM [470], and the CR [174, 208]. It is of interest that while the influence of the LC on premotor autonomic neurones in the PVN and CR is excitatory, it is inhibitory on neurones in the RVLM (see Fig. ()). Finally, the LC may modulate autonomic activity by projections to the cerebral cortex and amygdala [208, 293], structures which are known to influence the activity of premotor sympathetic neurones in the PVN [173, 420] and RVLM [437]. The projections of the LC to the amygdala [90, 218] and to the PVN [381, 430] have both been linked to the autonomic response to stress, consisting of generalised sympathetic activation. A schematic diagram outlining the autonomic neuronal network, highlighting the central position of the LC, is shown in Fig. ().

The activation of the LC results in a well-defined pattern of autonomic changes: in tissues receiving a predominantly sympathetic innervation (e.g., arterioles and sweat glands) there is an increase in activity, whereas in those receiving predominantly parasympathetic innervation (e.g., salivary glands) there is a decrease in activity. It should be noted that the pressor effect observed after LC activation is attenuated by the inhibition of the RVLM [470], resulting in only moderate increases in heart rate and blood pressure [412, 482]. Furthermore, in a tissue receiving a dual sympathetic/parasympathetic innervation (e.g., iris), where the two autonomic inputs have opposing effects, the effect of LC activation on sympathetic activity is enhanced by the inhibition of the parasympathetic output. The consequences of LC activation are, therefore, observable as an increase in pupil diameter [341, 342], attenuation of the light reflex response [22, 38, 40], moderate increases in heart rate and blood pressure [106, 154, 251, 412, 429, 482], suppression of the baroreflex response [192, 401], and a reduction in salivation [446]. The modulation of the baroreflex response by the LC may reflect to some extent the activity of central adrenergic neurones which have been shown to project to the LC (see Section 3.1.4.5 in Part I) and to be sensitve to changes in blood pressure [252].

Correlation between Arousal and Autonomic Function

The central role of the LC in the combined regulation of arousal and autonomic function is highlighted by the association between the level of arousal in pupillary activity. It has been shown that changes in the level of arousal are associated with changes in pupil diameter [186, 254] and spontaneous pupillary fluctuations in darkness [257, 507], and there is evidence that the pupillary changes directly reflect LC activity [354]. Indeed, the close relationship between level of arousal and pupil diameter has been exploited in the PST, which records pupil diameter over a period of eleven minutes. During the period of recording slow fluctuations appear in the diameter of the pupil (“pupillary fatigue waves”), and it has been shown that the power of these fluctuations can be used as a reliable index of the level of arousal [493]. As there is a close parallelism between fluctuations in the firing rates of LC neurones and fluctuations in pupil diameter (see Fig. ()), it is likely that the pupillary fatigue waves represent fluctuations in LC activity, and thus may provide a direct physiological indicator of the functioning of this important brainstem nucleus.

Scope of the Review

The activity of the LC can be altered through a variety of physiological manipulations such as the presentation of a noxious or anxiety-provoking stimulus or by variations in ambient temperature, through pharmacological manipulations such as the administration of drugs which act directly at the autoreceptors located on the neurones of the LC, that modify the reuptake or storage of noradrenaline, or that act indirectly to modify LC activity, through neuronal loss from the LC in aging, and through pathological changes that occur as a result of neurodegenerative disease (PD, AD) and brainstem trauma resulting in coma. In this review we attempt to delineate the effects of experimental manipulations and pathological changes on LC activity and hence on level of arousal and autonomic function.

PHYSIOLOGICAL MANIPULATION OF LOCUS COERULEUS ACTIVITY

LC neurone activity is determined by a number of varied inputs, as described in our companion paper (see Part I). Physiological manipulations, such as the presentation of a noxious or anxiety-provoking stimulus or an extreme in ambient temperature, can modulate the strength of these inputs, and therefore the extent of excitation or inhibition of the noradrenergic neurones, to alter the overall activity of the LC. The effect on LC activity resulting from these manipulations can often be detected via the measurement of resting pupil diameter and/or pupillary reflexes to sudden light stimuli, since the LC is so integral to pupillary control [444]; see above and Part I. For changes in cortical activity following LC activation, see Section 2.1.1. in Part I.

Noxious Stimuli

The LC is innervated by the sensory neurones of the dorsal horn of the spinal cord: this innervation provides a method of communicating nociceptive information to this nucleus [61, 82, 309]; see 3.1.6, Part I. Neurone activity within the LC is increased following the presentation of a noxious stimulus, measurable as an increase in electrical activity [109, 124, 220, 361, 412] and an increase in c-fos expression [56, 326, 327, 340, 394, 462, 478]; see [324] for a review. The pattern of LC neurone firing after the presentation of a noxious stimulus involves an initial burst of activity followed by a period of quiescence [420]. Interestingly, microinjection of the α2-adrenoceptor antagonist idazoxan into the LC, which is likely to result in an increase in LC activity (see section 3.2, below), has been reported to increase the responsiveness of LC neurones to noxious stimulation [420]. In addition, noradrenaline levels in both the LC and PVN, a projection area of the LC (see 2.2.2.2, part I), are increased following noxious stimulation [324, 374, 411], presumably as a result of an increase in noradrenaline synthesis in LC neurones. Indeed, the PVN has been implicated in pain perception. Interestingly, the increase in LC activity following the presentation of a noxious stimulus has been found to inhibit neurones of the basolateral nucleus of the amygdala and this inhibition may be involved in the formation of emotional memories following a noxious event [70].

It is expected that an increase in LC activity following noxious stimulation would, in general, increase sympathetic and decrease parasympathetic activity (see section 1.2, above), and this may be related to the paradigm of pupillary reflex dilatation, the best studied autonomic response to noxious stimulation. Pupillary reflex dilatation is observable in both experimental animals [177, 231] and human subjects [66, 237, 481, 504].

Interestingly, drugs that are known to modify LC activity (see 3.2, below) also affect pupillary reflex dilatation in a way consistent with the alteration in LC activity. Thus, manipulations which decrease LC activity in experimental animals (e.g., monoamine depletion by reserpine and alpha-methyl-para-tyrosine) antagonise pupillary reflex dilatation [175]. However, paradoxically, both an α2-adrenoceptor antagonist, yohimbine [175, 177] and an α2-adrenoceptor agonist, dexmedetomidine [237] have been reported to inhibit pupillary reflex dilatation. As the observations with yohimbine were made in cats and those with dexmedetomidine in humans, these findings can be reconciled by a well-documented species difference in the pupillary effects of drugs interacting with α2-adrenoceptors. It has been shown that agonists constrict and antagonists dilate the pupil in man but evoke effects in the opposite direction in cats, indicating the preferential action of these drugs at pre-synaptic α2-adrenoceptors in man and post-synaptic α2-adrenoceptors in the cat (see 3.2, below). In both man and the cat, the administration of an α2-adrenoceptor antagonist is expected to activate the LC and increase its sensitivity to further activation by noxious stimulation [409], which would be expected to lead to facilitation of pupillary reflex dilatation. However, in the cat this effect is likely to be masked by miosis, resulting from the activation of the EWN as a result of the blockade of post-synaptic inhibitory α2-adrenoceptors, leading to the apparent attenuation of pupillary reflex dilatation. On the other hand, the α2-adrenoceptor agonist is expected to reduce LC activity and thus attenuate the LC activation resulting from the noxious stimulation, manifesting as an apparent reduction in pupillary reflex dilatation. Indeed, this effect has been reported in man [237]. It should be noted that Larson and Talke [237] interpreted this finding on the basis of a postulated anti-nociceptive effect of dexmedetomidine, since they assumed that the LC had been completely “switched off” by the pre-treatment of their subjects with opiates.

A well-studied experimental paradigm of sympathetic activation by noxious stimulation in human subjects is the cold pressor test, evoked by a painful cold stimulus to the hand, which leads to both an increase in blood pressure and to pupil dilatation [454, 455]. This response has two interesting features. Firstly, it is not accompanied by a reduction in light reflex amplitude [455], as would be expected on the basis of increased LC activity, which could be predicted to lead to enhanced noradrenergic inhibition of the EWN. This observation raises the possibility that different populations of LC neurones may be responsible for mediating the sympathetic activating and parasympathetic inhibiting effects of the LC on pre-ganglionic autonomic neurones (see 5, below), where the cold pressor test may influence only the sympathetic pre-autonomic neurones in the LC. Secondly, while the increase in blood pressure evoked by the cold pressor test can be antagonised by diazepam, the increase in pupil diameter is resistant to it [189]. This observation may indicate that different structures may be involved in mediating the autonomic effects of the cold pressor test, the pupillary effect is likely to be mediated by the LC whereas the pressor effect by the PVN. Furthermore, while GABAA receptors occur in both the LC [71, 216, 314] and the PVN [158, 162, 212, 467], those in the LC are insensitive to diazepam [71], whereas those in the PVN, like GABAA receptors in general, probably are sensitive to this drug.

Anxiety

Anxiety is generally defined as an emotional state evoked by threatening stimuli, although pharmacological intervention can also produce increased anxiety levels [443]. It is known that the amygdala is critical to the generation of anxiety and anxious responses [90, 218, 242] and there is a two-way excitatory connection between the amygdala and the LC (see Part I). It, therefore, follows that LC activation could be expected to lead to anxiety through the activation of the amygdala and, conversely, anxiety producing stimuli that increase the activity of the amygdala could be expected to lead to LC activation. This circular argument makes it difficult to determine in a given situation whether anxiety is produced by the activation of the LC or whether the LC is activated as a result of increased anxiety. In certain situations, however, the two processes can be delineated (see below).

Anxiogenic Effect of LC Activation

Electrical stimulation of the LC evokes fear-related behavioural responses [365], which can be alleviated by clonidine, morphine, and diazepam [365], drugs known to suppress LC activity (see sections 3.1 and 3.2). Administration of the α2-adrenoceptor antagonist yohimbine activates the LC (see section 3.2), which in turn produces an increase in anxiety [141, 282, 300, 453]. Conversely, bilateral lesions of the LC [363] or of the ascending noradrenergic projection arising from it [475], lead to a reduction in fear-related responses.

LC Activation by States of Anxiety

It is well recognized that patients suffering from different forms of anxiety disorder show evidence of altered autonomic regulation [443]. Many of the changes reported are consistent with increased LC activity, leading to enhancement of sympathetic discharge and inhibition of parasympathetically mediated functions. Thus, it has been reported that anxious patients show hypersensitivity of their eccrine sweat glands to intradermally injected muscarinic cholinoceptor agonists, such as carbachol, a finding indicating increased sympathetic activity. Eccrine sweat glands receive a cholinergic sympathetic innervation (see Fig. ()), and their activity, and also their sensitivity to cholinoceptor agonists, is modulated by impulse traffic in the sympathetic fibres, high firing rates being associated with high, and low firing rates with low sweat gland activity/sensitivity [443]. Furthermore, it has been shown that patients suffering from generalized anxiety disorder have attenuated light reflexes [22], consistent with increased noradrenergic inhibition of the EWN originating from the LC.

Experimental situations of induced fear increase anxiety via the activation of the amygdala and lead to LC activation [68, 69, 85, 360, 364]. The experimental paradigm of conditioned fear can be used to produce states of fear and anxiety in the laboratory and thus can be used to assess the modulation of the LC during these states. Fear conditioning, where a neutral stimulus (CS) is temporally associated with an aversive stimulus (US) and thus gains an aversive character itself, produces an increase in LC activity as demonstrated by increased c-fos expression when the CS is presented alone [195, 253]. In addition, rats selectively bred to demonstrate high levels of anxiety show increased c-fos expression within the LC [376] and in human volunteers subliminal fear signals have been found to elicit activity within the LC, as detected by functional neuroimaging [250].

The increase in LC activity following the conditioned fear paradigm is accompanied by an increase in arousal and sympathetic function. For example, REM sleep has been observed to concomitantly decrease in response to the presentation of a fear conditioned stimulus [253] and this is consistent with the activation of the LC and the expected increase in arousal. The activation of the sympathetic nervous system by conditioned fear results in a variety of changes in autonomic activity and in particular there are two measurable changes in the pupil: an increase in resting pupil diameter and a reduction in the amplitude of the light reflex response [36, 38, 39, 40, 42]. Furthermore, it has been reported that patients suffering from generalised anxiety disorder have attenuated light reflex responses [22]. These pupillary effects are likely to reflect the dual influence of LC activation on the pupil: the increase in resting pupil diameter may suggest an increase in sympathetic outflow and/or a decrease in parasympathetic outflow to the iris, whereas the decrease in light reflex amplitude is the result of inhibition of the parasympathetic outflow to the iris (see above). Interestingly, of the two pupillary effects of conditioned fear, evoked by the threat of a mild electric shock, only the reduction in light reflex response amplitude was related quantatively to the degree of subjective anxiety, whereas the increase in pupil diameter was not [42], and only the reduction in light reflex response amplitude was susceptible to antagonism by the anxiolytic drug diazepam, whereas the increase in pupil diameter was not [36, 40]. These observations suggest that conditioned fear may preferentially activate the pre-parasympathetic neurones in the LC via the amygdala, leading to the anxiety-dependent reduction in light reflex response amplitude, whereas it may cause some indirect activation of the presympathetic neurones via the arousal system, resulting in some increase in pupil diameter. The differential effects of diazepam on the two components of the pupillary anxiety response may reflect the fact that diazepam may increase the GABAergic inhibition of amygdala neurones, thus leading to the attenuation of the fear-induced activation of pre-parasympathetic LC neurones, whereas it may not be able to modify the activity of pre-sympathetic LC neurones which do not contain diazepam-sensitive GABA receptors [71]; see also Section 3 and Fig. ().

Stress exposure, which may also be classed as an anxiety-provoking situation, is also associated with enhanced LC activity [124] and with increased noradrenaline release [51, 453, 101, 322, 323], following the presentation of a stressful stimulus in experimental animals, such as the rat and cat Indeed, chronic stress exposure produces long-term alterations in LC firing and noradrenaline release [51, 398, 321, 322]. For reviews on the activation of the central noradrenergic system by exposure to stressful stimuli, see refs. 324, 328; see also Section 2.1.

The enhancement of LC activity by stressful stimuli can be detected by changes observed in autonomic activity. Tasks inducing stress via high levels of cognitive load have been found to increase pupil diameter and reduce light reflex amplitude compared to no or low cognitive load tasks [426, 427]. Furthermore, these studies have identified both an increase in sympathetic activity and a decrease in parasympathetic activity in the modulation of pupil diameter following the application of a cognitive load, consistent with LC activation. Recently it has been shown that remembering emotionally-loaded material results in activation of the LC in humans, as detected by functional magnetic resonance imaging (fMRI), together with an increase in pupil diameter [428].

Role of the LC in Mediating Fear Responses

It has been proposed that an increase in LC activity mediates the behavioural responses associated with fear and anxiety [67], and this is supported by observations associating the increased firing of the LC following the presentation of fear-inducing stimuli with behavioural manifestations of fear [51]. For example, α2-adrenoceptor knockout mice lacking the physiological brake of LC activity (see section 3.2) show both an increase in LC activity and an increase in freezing responses in the conditioned fear paradigm [92], whilst lesions of the LC attenuate the freezing response both to the unconditioned aversive stimulus and to the conditioned cue [306].

An interesting possibility that results from the interaction of the amygdala and the LC (see above) is that activation of the LC may contribute to the fear-potentiated startle response. The startle response involves rapid involuntary contractions of facial and skeletal musculature in response to a sudden intense stimulus, for example, a loud sound, and this reaction is measurable in man as an EMG response from the orbicularis oculi muscle (eyeblink startle response). The LC is likely to be involved in modulating the startle response since the LC projects to the motoneurones in the facial nucleus [208]; see 2.3.5.1, Part I, which innervates the orbicularis oculi muscle. This projection is likely to exert a facilitatory influence on the motoneurones as demonstrated by the enhancement of motoneurone activity evoked by the extracellular microiontophoretic application of noradrenaline to the facial motoneurones [359, 471, 491]. The administration of an α2-adrenoceptor agonist, which reduces LC activity, has been found to reduce the startle response [3, 4, 233, 379], whereas the α2-adrenoceptor antagonist yohimbine, which is known to enhance LC activity [200, 413, 453], enhances the amplitude of the acoustic startle response [294]. It is possible that this modulation of the startle response arises from the withdrawal or potentiation of the excitatory input to the orbicularis oculi muscle from the LC, leading to a reduction or enhancement in the tone of this muscle respectively [379]. Indeed, the wakefulness-promoting drug modafinil, assumed to act through enhancing the activity of the LC [184, 383]; see also 3.2.1.2, was found to antagonise the reduction in startle response amplitude found following clonidine administration [379].

This startle response can be potentiated by the threat of an electric shock, inducing a state of fear via the activation of the amygdala [93]. This paradigm is therefore used as an important laboratory model of anxiety, both in animals [301, 369, 408, 498] and humans [11, 144, 147, 210]. The LC may contribute to the activation of the startle pathway in the fear-potentiated startle paradigm in two ways. Firstly, the acoustic stimulus itself may prime motoneurone activity via the LC: the acoustic stimulus leads to the activation of the caudal pontine reticular nucleus, the major pre-motor integrator of the startle response [226], which activates not only the facial motoneurones but also the LC [379], which in turn results in the facilitation of motoneurone activity (see above). Secondly, the activation of the amygdala by fear-conditioning may increase LC activity (see above) and thus the noradrenergic output of this nucleus. In this way, the dual excitatory input to the LC from the caudal pontine reticular nucleus and the amygdala enhances the tone of the motoneurones of the facial nucleus and contributes to the fear-potentiated startle response. Interestingly, the administration of the α2-adrenoceptor agonist clonidine, which reduces LC activity, has been found to result in a reduction in the fear-potentiated startle response [94], whilst the administration of the α2 adrenoceptor antagonist yohimbine, which is known to enhance LC activity, enhances the fear-potentiated startle response [94].

Ambient Temperature

Preoptic nuclei of the hypothalamus, including the VLPO, are intimately involved in temperature regulation [108, 387], and neurones in these areas change their activities in response both to increases and decreases in body temperature [108]. Body temperature in turn may be influenced by ambient temperature [15]. Furthermore, neurones in the VLPO project profusely to the LC (see 3.1.3.1, Part I). Therefore, shifts in ambient temperature induce changes in LC activity via the mediation of the anterior hypothalamus.

Acute and chronic modulation of ambient temperature has different effects on LC activity, acute temperature changes increasing and chronic exposure decreasing LC activity. The increase in LC activity in response to acute cold stress has been demonstrated as increases in c-fos expression [223, 508] and in the activity of the rate-limiting enzyme in noradrenaline synthesis, tyrosine hydroxylase [72, 320]. Similarly, acute high ambient temperature increases LC neurone activity [295]. Activation of the LC by high ambient temperature (40°C) is associated with activation of the sympathetic nervous system, manifesting as increases in body temperature, heart rate, carbachol-evoked sweating, and physiological finger tremor [15] and a reduction in the recovery time of the pupillary light reflex response [247]. Some of these sympathetic responses (increases in body temperature and heart rate) could be antagonised by clonidine [15] consistent with the involvement of the LC. In contrast, warm ambient temperature (33°C) has no effect on LC neurone firing [223]. It is of interest to note that acute thermal cutaneous stimulation also activates neurones of the LC, via the release of excitatory amino acids from the nucleus paragigantocellularis [153].

Chronic cold stress has been found to reduce LC neurone activity, measurable as a reduction in tyrosine hydroxylase activity and an increase in α2-adrenoceptor mRNA expression in the LC [113]. Similarly, chronic high ambient temperature reduces LC activity, measurable as a reduction in tyrosine hydroxylase activity [130].

PHARMACOLOGICAL ALTERATIONS OF LOCUS COERULEUS ACTIVITY

Drugs can modify LC activity either directly by interacting with different aspects of the function of the noradrenergic neurones, i.e. by modifying firing rate and/or release via an action at inhibitory autoreceptors, modifying the storage of the neurotransmitter in presynaptic vesicles, and interfering with the elimination of synaptically released noradrenaline via the reuptake mechanism. Drugs may also have an indirect effect on LC activity via the modification of the activities of excitatory or inhibitory inputs to the LC.

Drugs with a Direct Action on LC Activity

Drugs Acting at Autoreceptors

LC neurone activity can be modulated via the administration of drugs that stimulate or block the inhibitory autoreceptors located presynaptically on the LC neurones (see 3.2, Part I). Autoreceptors occur both on the cell body (somatodendritic autoreceptors) and at the nerve ending (terminal autoreceptors). The somatodendritic autoreceptors modulate the firing rate of the neurone whereas the terminal autoreceptors modulate the release of the neurotransmitter. Exposure to the α2-adrenoceptor agonist clonidine has been used to activate these autoreceptors, whilst the α2-adrenoceptor antagonist yohimbine has been used to block them. Administration of clonidine to the LC hyperpolarises the neuronal membrane via an increase in potassium conductance leading to a reduction of the spontaneous firing rate of the neurones, resulting in the inhibition of the LC [5, 6, 114, 273, 303, 438, 439, 494, 496]. The inhibition of LC activity by clonidine is accompanied by a fall in plasma noradrenaline concentration [182]. Other α2-adrenoceptor agonists such as dexmedetomidine have a similar effect on LC activity [73, 209]. In contrast, administration of yohimbine to the LC increases neuronal firing [200, 300, 303, 413, 453] and noradrenaline release [487]. Other α2-adrenoceptor antagonists (BRL44408, RS79948, RX821002) have also been found to have an excitatory influence on the LC, observable as an increase in noradrenaline release at LC terminal regions [115].

Noradrenergic pathways arising from the LC may mediate either excitatory effects, via the activation of α1-adrenoceptors, on the target cells (ie. in the cerebral cortex and IML) or inhibitory effects, via the activation of α2-adrenoceptors located on the target cells (eg. in the VLPO, EWN, RVLM) (see Figs. () and ()). Since the inhibitory effect is mediated by the same post-synaptic receptors that also attenuate the activity of LC neurones in a presynaptic location, i.e., α2-adrenoceptors, the net effect of a α2-adrenoceptor agonist depends on the relative activation of pre- and post-synaptic receptors (see Table ). We wish to consider the effect of clonidine on seven noradrenergic pathways, five inhibitory and two excitatory, whose roles in the regulation of four functions (arousal, pupil control, blood pressure, salivation) have been extensively studied (see Fig. () and Table ). There are five sites where clonidine interacts with inhibitory α2-adrenoceptors: LC (autoreceptors; 1), VLPO (2), EWN (3), RVLM (4) and salivatory nuclei (5). The “switching off” of LC activity by clonidine via activation of inhibitory autoreceptors results in attenuation of both the excitatory (stimulatory) effects and the inhibitory effects (disinhibition) mediated by noradrenergic pathways arising from the LC. On the other hand, activation of post-synaptic inhibitory α2-adrenoceptors results in potentiation of the noradrenergic inhibition of the target cells in the VLPO, EWN, RVLM and salivatory nuclei. The net effect of clonidine on an inhibitory noradrenergic pathway therefore will reflect the balance between the results of the opposing pre-synaptic and post-synaptic effects: if the pre-synaptic effect predominates, the result will be attenuation of the function and if the post-synaptic effect predominates, the effect will be the augmentation of the function. α2-Adrenoceptor antagonists (e.g., yohimbine) exert effects on the four functions studied which are opposite to those of the agonists, reflecting the blockade of both autoreceptors and post-synaptic receptors.

Arousal

α2-Adrenoceptor agonists have potent sedative effects due to the activation of the autoreceptors on LC neurones resulting in the “switching off” of the activity of these neurones. The reduction in LC activity leads to the attenuation of the noradrenergic stimulation of the cerebral cortex and disinhibition of the VLPO which in turn leads to increased inhibition of the wakefulness-promoting histaminergic pathways originating from the tuberomamillary nucleus (TMN; see 1.1 above and 2.2.2.1 in Part I). It should be noted, however, that α2-adrenoceptor agonists also activate inhibitory post-synaptic α2-adrenoceptors in the VLPO, which is expected to lead to an increase in the level of arousal. This effect usually is masked by the presynaptic effect of these drugs on LC neurones resulting in a sedative effect. However, in some species (cats, rats, and mice) the stimulant effect of α2.-adrenoceptor agonists has been observed (see 3.1.1.6, below). The sedative effect of clonidine in humans is well demonstrated in the laboratory [182, 184, 296, 342, 379, 421, 486], and it is a known drawback to the clinical use of this drug as an anti-hypertensive agent [45, 261]. Other α2-adrenoceptor agonists, for example dexmedetomidine, have also been shown to have pronounced sleep-promoting effects [269, 388], and this drug is used clinically as an anaesthetic. Interestingly, the opioid analgesic tramadol also possesses α2-adrenoceptor stimulating activity and completely inhibits LC activity [31], and has been shown to be associated with sedation as a side effect [243, 249]. These drugs have been shown to promote SWS [99]. In contrast to clonidine, the α2-adrenoceptor antagonist yohimbine has been shown to possess some alerting effects [342], and the increase in wakefulness has been demonstrated to be associated with cortical desynchronisation [99].

Pupil Control

α2-Adrenoceptor activation in the LC leads to a reduction in sympathetically-mediated pupil dilatation due to attenuation of the activity of the coeruleo-spinal pathway and also a reduction in noradrenergically-mediated inhibition of the EWN (See Fig. ()). Post-synaptic receptors in the EWN are also stimulated by α2-adrenoceptor agonists resulting in an increase in noradrenergic inhibition of the EWN. The pupillary effects of clonidine indicate that in man the pre-synaptic effect of the drug is likely to predominate (see Table ). α2-Adrenoceptor agonists cause a reduction in pupil diameter (miosis); [184, 341, 379]. It has been shown that this effect is more pronounced in light than in darkness, consistent with attenuation of the noradrenergic inhibition of parasympathetic outflow to the iris [444]. In agreement with this observation, it has been shown that clonidine [39] and dexmedetomidine [238] enhance the amplitude of the light reflex response. Remarkably, µ opiate receptor agonists (eg. morphine) also cause miosis in man, likely to reflect the close association between α2-adrenoceptors and µ opiate receptors on LC neurones (see below, 3.1.1.6).

In contrast to clonidine, the α2-adrenoceptor antagonist yohimbine increases pupil diameter in human subjects [296, 341, 342]. Furthermore, like the effect of clonidine on the pupil, this effect was light-dependent, suggesting an increase in the noradrenergic inhibition of parasympathetic outflow to the iris.

Blood Pressure

The LC exerts both direct and indirect effects on the activity of preganglionic sympathetic neurones in the IML. The direct effect is mediated via a descending excitatory noradrenergic pathway, whereas the indirect effect involves the modulation of the activity of other premotor sympathetic nuclei (RVLM, caudal raphe nuclei, A5 noradrenergic neurones, C1 adrenergic neurones) projecting to the IML [27, 422] (see also Section 2.3.2 in Part I). While the noradrenergic projections from the LC to the serotonergic neurones of the caudal raphe, the A5 noradrenergic and C1 adrenergic neurones are likely to be excitatory, the projection to the RVLM is inhibitory (see Fig. ()). The RVLM itself exerts a sympathoexcitatory effect via a glutamatergic projection to the IML (see 2.3.2.1, Part I). Therefore, the direct noradrenergic projection to the IML and the indirect projection via the RVLM have opposing effects on blood pressure: the effect of the stimulation of preganglionic sympathetic neurones is counteracted by the removal of the sympathoexcitatory influence of the RVLM. α2-Adrenoceptor agonists have robust hypotensive effects due to the summation of their direct sympatholytic effect resulting from simulation of presynaptic autoreceptors and augmentation of the noradrenergic inhibition of the RVLM resulting from activation of post-synaptic α2-adrenoceptors in this nucleus (see Table ). The hypotensive effects of clonidine are well documented [15, 45, 126, 183, 185, 261, 296, 342, 379, 421, 486]. Furthermore, clonidine is marketed as an effective anti-hypertensive drug.

The role of the RVLM in mediating the hypotensive effect of α2-adrenoceptor agonists is well demonstrated [47, 163, 238]. Indeed, microinjection of clonidine directly into the RVLM results in hypotension and it is suggested that these neurones are tonically inhibited by α2-adrenoceptor activation [474]. The input from the LC is also believed to contribute to the baroreceptor reflex pathway outlined above through activation of these α2-adrenoceptors [154, 308], and this is supported by studies of α2A knockout mice that demonstrate impaired baroreceptor reflex function [308]. Other α2-adrenoceptor agonists, such as dexmedetomidine also exert a pronounced depressor effect [135, 269]. The reduction in heart rate and blood pressure by dexmedetomidine has been found to result from a reduction in sympathetic activity [269] and an augmentation of parasympathetic activity [336], consistent with LC inactivation.

Again, yohimbine modifies blood pressure in a direction that is opposite to that produced by clonidine: pressor responses have been reported [148, 204, 342, 483], consistent with disinhibition of pre-synaptic autoreceptors in the LC and post-synaptic inhibitory receptors in the RVLM. The involvement of the RVLM in the hypertensive action of α2-adrenoceptor antagonists is highlighted by the observation that microinjection of methoxy-idazoxan into this area of the brainstem resulted in an increase in blood pressure [474].

It should be noted that α2-adrenoceptors also occur in peripheral blood vessels where they mediate a vasoconstrictor effect [77, 299]. The vasoconstrictor effect of clonidine, however, does not lead to an increase in systemic blood pressure since its effect on blood pressure is superseded by the central sympathoinhibitory effect of the drug. However, when the influence of central sympathoinhibition is disrupted due to lesions of the spinal cord, clonidine evokes an increase in blood pressure due to its peripheral vasoconstrictor effect [393].

Salivation

Salivary glands are controlled mainly by a parasympathetic innervation, the preganglionic neurones in the salivatory nuclei being located in the brainstem (see 2.3.1.2, part I). The LC exerts an inhibitory influence on these neurones. Clonidine and other α2-adrenoceptor agonists lead to a substantial reduction in salivary output [15, 45, 184, 207, 261, 342, 379, 388, 421, 446, 486] consistent with the preferential activation of post-synaptic α2-adrenoceptors on salivatory neurones (see Table ). On the other hand, α2-adrenoceptor antagonists like yohimbine lead to hypersalivation by blocking inhibitory α2-adrenoceptors on salivatory neurones and thus attenuating noradrenergic inhibition of the activity of these neurones [204, 292, 342, 446]. It should be noted, however, that α2-adrenoceptor agonists may reduce and α2-adrenoceptor antagonists may enhance salivation not only by interacting with α2-adrenoceptors on preganglionic neurones in the salivatory nuclei but also with release inhibiting α2-adrenoceptors on the terminals of postganglionic cholinergic neurones in the salivary glands [292, 446].

Temperature

There is evidence that the VLPO is intimately involved in temperature regulation [387] and also that this structure receives a dense noradrenergic innervation from the LC (see 2.2.2.1, Part I). Interestingly, the LC is involved in modulating the hypothalamic regulation of body temperature. It has been reported that the LC is involved in lipopolysaccharide-induced fever [362], which is attenuated by LC lesions [9]. Furthermore, LC lesions reduce brain temperature [142] and hypothermia induced by hypoxia [112].

Clonidine, probably due to a reduction in LC activity, leads to a fall in body temperature both in experimental animals [241, 366, 461, 511] and humans [15, 138]. The hypothermic effect of clonidine is antagonised by yohimbine [366, 461] and by high ambient temperature, leading to an increase in body temperature [15].

α2-Adrenoceptor Associations

Opiate Receptors

μ-Opiate receptors occur on LC neurones (see 3.2 in Part I), and opiate peptides (enkephalins, dynorphins) are highly concentrated in the LC [120, 297, 513]. It has been shown that μ-opiate receptors are co-localised with α2-adrenoceptors in the LC and their activation results in cellular inhibition via a shared potassium channel [75, 121]; see also 3.2, Part I). Morphine, like clonidine, reduces LC neurone activity [395] and induces synchronous oscillatory discharges [518]. Therefore, it is not surprising that there is a considerable pharmacological overlap between the actions of α2-adrenoceptor and opiate receptor-selective agonists. Thus, it has been reported that chronic treatment with morphine results in up-regulation of α2-adrenoceptors in the brain [155].

Morphine, like clonidine, is highly sedative in man, and this effect is likely to be due to attenuation of the activity of the LC (see Fig. () and Table ). Indeed, microinjection of morphine directly into the LC has been found to reduce arousal, observed as an increase in SWS [131]. Other opiate receptor agonists have also been found to produce sedation (oxycodone [476], tramadol [243, 249], codeine [277]).

Morphine, like clonidine, has been observed to reduce pupil diameter in man [104, 179, 225, 479], and a ‘pinpoint pupil’ is a clinical hallmark of opiate addiction. This effect of morphine is consistent with a decrease in LC activity leading to the disinhibtion of the parasympathetic light reflex mechanism. Other opiates share this effect (oxycodone [476], tramadol [225, 512], codeine [225, 479]). The close association between α2-adrenoceptors and μ-opiate receptors in the pupil control system is highlighted by the observation that the α2-adrenoceptor antagonist yohimbine can antagonise the mydriatic effect (see 3.2.6, below) of morphine in the rat [224].

An important therapeutic implication of the pharmacological association between α2-adrenoceptor and μ-opiate receptor mediated mechanisms is the usefulness of the α2-adrenceptor agonists clonidine and lofexidine to alleviate the opiate withdrawal syndrome [143]. Indeed, it has been shown that the LC plays an important role in the processes underlying opiate withdrawal [20, 228, 236].

Imidazoline Receptors

Clonidine and some other α2-adrenoceptor agonists with an imidazoline structure may interact not only with α2-adrenoceptors but also with imidazoline receptors [46, 329]. Imidazoline receptors have been subdivided into three subtypes (I1, I2 and I3) [165]. I1-imidazoline receptors have been shown to occur in the RVLM, and it has been proposed that these receptors are the most important in mediating the cardiovascular effects of I1-receptor agonists, such as moxonidine. The co-localisation of α2-adrenoceptors and imidazoline receptors may be restricted to the RVLM since imidazoline receptors have not been identified in the LC [447] and there is evidence suggesting that they may also be absent from salivatory nuclei since moxonidine does not reduce salivation [156]. The depressor effect of non-selective drugs, such as clonidine, would reflect an action both at imidazoline receptors and α2-adrenoceptors in the RVLM [156] and at α2-adrenoceptors in the LC. On the other hand, selective (non-imidazoline) antihypertensive drugs would exert their depressor effect by stimulating α2-adrenoceptors in the LC. It should be noted, however, that the nature of imidazoline receptors as an entity has been questioned and the relationship to α2-adrenoceptors remains controversial [164, 229].

Relationship between Pre-synaptic and Post-synaptic Effects

α2-Adrenoceptors and μ-opiate receptors occur both pre-synaptically in the LC and post-synaptically on target cells receiving a noradrenergic innervation from the LC (see Fig. ()). The effect of agonists acting at these receptors will be determined by the relationship of the effects resulting from the activation of receptors at the pre-synaptic and post-synaptic sites. In the case of arousal and pupil diameter regulation, the action of the agonists at the two sites leads to opposing effects: activation of α2-adrenoceptors or μ-opiate receptors in the LC results in sedation and pupil constriction, whereas activation of the same receptors in the target cells (VLPO and EWN, respectively) leads to increase in alertness and pupil dilatation. Interestingly there is a remarkable species difference regarding the action of α2-adrenoceptor and μ-opiate receptor agonists on arousal and pupil diameter, and this species difference is likely to reflect the preponderance of the action of these drugs at either pre-synaptic or post-synaptic receptors (see Table ). Thus, while the α2-adrenoceptor and μ-opiate receptor agonists are uniformly sedative in man, dog and rabbit, they often have alerting effects, usually demonstrated as EEG activation, in cats, rats and mice. It should be noted; however, that sedative effects of α2-adrenoceptor agonists have also been demonstrated in cats [280], rats [305], and mice [167], and there is evidence that the activation of presynaptic α2-adrenoceptors in the LC is responsible for this effect [168, 305]. There is also a species difference regarding the pupillary effect of yohimbine: whilst in humans it produces mydriasis, in cats and rats it evokes miosis [177].

As pre- and post-synaptic receptors exist in all the species studied, it is likely that in man, dog and rabbit where the presynaptic effect predominates this reflects the generally higher sensitivity of pre-synaptic autoreceptors compared to post-synaptic receptors, leading to preferential activation of pre-synaptic receptors at lower dosage levels of α2-adrenoceptor and μ opiate receptor agonist. The presence of post-synaptic receptor activation in these species is highlighted by the observation that pupil dilatation has been observed in two human patients with high plasma morphine concentrations [397], and clonidine, while it is highly sedative in dogs at smaller doses, evokes behavioural stimulation at higher dosage levels [180]. However, in the cat, rat and the mouse where the post-synaptic effect usually predominates, it is likely that the pre-synaptic effect is masked by the consequences of post-synaptic receptor activation.

Drugs Interacting with Reuptake

Reuptake of released noradrenaline into the nerve terminal is the principle way of terminating the synaptic action of the transmitter. Reuptake involves the operation of an active membrane pump (noradrenaline transporter; [10, 53, 274]. Inhibitors of the transporter result in attenuation of reuptake leading to potentiation of the effect of the transmitter on the post-synaptic cell. Inhibitors of noradrenaline reuptake are expected to enhance the post-synaptic effects of LC activation in each target area. We shall consider the same four functions (i.e., arousal, pupil control, blood pressure control, salivation) as discussed in relation to modulation by autoreceptors (see 3.2 above and Fig. ()).

The noradrenaline transporter has been indentified on noradrenergic neurones in the LC using the highly selective noradrenaline uptake inhibitor nisoxetine [405, 456]. Noradrenaline uptake inhibitors can influence the removal of noradrenaline released from dendrites in the LC leading to increased activation of inhibitory autoreceptors via the increased noradrenaline concentration resulting in a reduction in LC activity [145]. This effect, however, is likely to be superseded by the effect of noradrenaline uptake inhibition at the nerve terminals since while both amphetamine [7, 86] and cocaine [89, 348, 349, 350] reduce the activity of the LC, they also increase the concentration of noradrenaline in the synaptic gap at the target areas of noradrenergic terminals [86] leading to increases in LC-mediated functions such as arousal and pupil diameter (see below).

Inhibition of noradrenaline uptake at the excitatory noradrenergic synapses in the cerebral cortex and in wakefulness-promoting nuclei, together with a similar action at inhibitory noradrenergic synapses in the VLPO, is expected to lead to an increase in arousal. Noradrenaline uptake inhibition in general has been associated with an alerting effect. Thus, it has been shown that the noradrenaline uptake inhibitors indeloxazine [403] and S33005 [62] increase alertness in experimental animals.

Although the psychostimulant actions of amphetamine and cocaine are usually attributed to the blockade of the reuptake of dopamine, these drugs are also potent inhibitors of noradrenaline reuptake [495]. These drugs produce robust increases in arousal (amphetamine [157, 171]; cocaine [492]). The wakefulness-promoting drug modafinil, which is not classified as a psychostimulant, also increases alertness [184, 187, 380]; see 3.1, above) and inhibits the reuptake of both dopamine and noradrenaline [262], and the site at which noradrenaline uptake inhibition may be most relevant has been identified as the inhibitory noradrenergic synapse on VLPO neurones [128].

A number of antidepressants have been developed whose only or principal action is the inhibition of noradrenaline reuptake (e.g., reboxetine, venlafaxine, atomoxetine, duloxetine). Some of these drugs also have, albeit relatively weak, alerting effects. Reboxetine has been claimed to be an “activating” antidepressant improving social activity in depressed patients [98] and both reboxetine and atomoxetine are used as alternatives to psychostimulants in the treatment of attention deficit hyperactivity disorder [517]. Reboxetine has also been shown to increase arousal and suppress REM sleep in rats [227]. Phentermine, an anorectic agent used in the treatment of obesity, also inhibits noradrenaline and dopamine reuptake and has been shown to increase wakefulness in rats [371].

Inhibition of noradrenaline uptake is expected to potentiate the noradrenergic excitation of preganglionic sympathetic neurones in the IML, the stimulant effect of noradrenline at the neuroeffector junction in the iris, and the noradrenergic inhibition of the EWN. Indeed, both amphetamine [151, 157, 176, 351] and cocaine [202, 351, 497] have been demonstrated to increase pupil diameter consistent with such an action. Furthermore, there is evidence that amphetamine-induced pupil dilatation is related to the inhibition of parasympathetic output [224], consistent with an increase in the noradrenergic inhibition of the EWN.

It has been shown that both reboxetine [445] and venlafaxine [41] cause an increase in pupil diameter and inhibit the light reflex response. Although the increase in pupil diameter may simply reflect noradrenaline reuptake in the iris, leading to the enhancement of sympathetically-mediated pupil dilatation, the inhibition of the light reflex demonstrates the involvement of an action at the noradrenergic synapse on EWN neurones. Consistent with these findings, the predominantly noradrenergic tricyclic antidepressant desipramine also increases pupil diameter [406] and inhibits the light reflex [459]; however, these effects may have been contaminated by an interaction of the drug with muscarinic cholinoceptors.

Noradrenaline uptake inhibition is expected to lead to augmentation of blood pressure [279], partly due to potentiation of the central sympathoexcitatory effect of the noradrenergic input to preganglionic sympathetic neurones and partly to potentiation of noradrenergically-mediated vasoconstriction in the periphery. This pressor effect is expected to be attenuated by potentiation of the noradrenergic inhibition of the RVLM. This attenuation is likely to be significant since noradrenaline reuptake inhibitors result in only moderate increases in blood pressure.

Administration of both amphetamine [59, 157, 264, 307] and cocaine [178, 284, 307] is associated with increases in blood pressure. Reboxetine [445], venlafaxine [2] and duloxetine [458] have all been reported to cause modest increases in blood pressure.

Potentiation of the noradrenergic inhibition of the salivatory nuclei, as a result of noradrenaline reuptake inhibition, is expected to result in a reduction in salivary output. Indeed, both reboxetine [445] and venlafaxine [2] have been shown to reduce salivation. These observations show that a reduction in salivation by an antidepressant is not necessarily due to muscarinic cholinoceptor blockade in the salivary glands, as generally assumed, but may reflect the interaction of the drug with central noradrenergic mechanisms [445].

Drugs Interacting with Storage

Noradrenaline is stored in synaptic vesicles in the nerve terminal, and its accumulation in the storage vesicles is via an active membrane pump (vesicular monoamine transporter 2, VMAT2; [516]). VMAT2 is not specific for noradrenaline, and is responsible for transporting also dopamine and serotonin into storage vesicles in the appropriate nerve terminals. VMAT2 is inhibited by some drugs such as reserpine and tetrabenazine, leading to the initial release of the monoamine followed by depletion of the stores, resulting in reduction/cessation of release [107]. While dopaminergic neurones show preferential sensitivity to depletion by tetrabenazine [449]; [132], reserpine leads to near equal depletion of all three monoamines [406]. The depletion of noradrenaline from central noradrenergic neurones leads to the “switching off” of the LC system, whereas depletion of noradrenaline from peripheral noradrenergic neurones results in a marked sympatholytic action [436].

Early work with the depleting agents carried out in the 1960s has described the consequences of noradrenaline depletion on functions mediated by the LC system, and more recent information relating to the functional neuroanatomy of the system (see Fig. ()) enables us to interpret these effects. Thus, administration of reserpine leads to sedation [436], which may be related to reductions in the excitatory influence of the LC on the cerebral cortex and other wakefulness-promoting nuclei and of the noradrenergic inhibition of the sleep-promoting VLPO. The “switching off” of the noradrenergic inhibition of the EWN is expected to lead to increased activity of this preganglionic parasympathetic nucleus. Indeed, it has been shown that reserpine causes miosis, which is more pronounced at ambient illumination than in darkness, and potentiates the light reflex [43]. Reserpine also leads to marked hypotension, presumably due to the combination of its central and peripheral sympatholytic effects [436]. Reserpine-induced noradrenaline depletion has also been demonstrated to be associated with an increase in salivary output [43], which is likely to be due to the removal of the tonic noradrenergic inhibition of salivatory nuclei.

Drugs Indirectly Modifying LC Activity

As reviewed in Part I, the LC receives afferent inputs from a large number of sources. In this section we wish to restrict ourselves to reviewing modifications in LC activity by afferent inputs arising from the sleep-arousal network (see Fig. ()). Stimulant and sedative drugs, apart from directly influencing LC activity (see 3.1, above), often exert an indirect effect on the LC via acting at different sites in the sleep-arousal network.

Stimulant Drugs

Adenosine Receptor Antagonists

Adenosine accumulates during wakefulness and plays a role in the initiation of sleep, via activation of A1 and A2 adenosine receptors [117, 466]. The sleep-inducing effect of adenosine is mediated partly via inhibition of wakefulness-promoting nuclei [287] and partly via stimulation of sleep-promoting nuclei [129, 190], which are known to project to the LC (see Fig. ()).

Caffeine is an adenosine receptor antagonist which is widely available and used extensively in the general population as a wakefulness-enhancing compound. The drug produces robust increases in arousal [25, 54, 213, 335, 488, 522] and has been shown to enhance LC activity [28, 100]. Administration of caffeine also produces increases in heart rate [194], blood pressure [194, 315, 464] and temperature [229], consistent with activation of the sympathetic nervous system. Interestingly, caffeine antagonises the sedative and autonomic effects of clonidine [417], a drug known to reduce LC activity (see 3.1, above).

Drugs Interacting with the Mesocoerulear Pathway

The dopaminergic system plays an important role in the maintenance of arousal [258] and psychostimulants such as amphetamine and cocaine are potent activators of this system by inhibiting the dopamine transporter and facilitating dopamine release [48, 368]. The alerting effect of dopaminergic drugs may partly be mediated via the LC since it has been shown that this nucleus receives excitatory inputs both from the VTA (mesocoerulear pathway) and vPAG (see 3.1.4.1 and 3.1.4.4, Part I).

Modafinil is a novel wakefulness-promoting drug used in the treatment of EDS in narcolepsy [468, 469] and it has been shown to alleviate the EDS associated with a number of other conditions (PD [310]; idiopathic hypersomnia [199]; night shift sleep disorder [480]; obstructive sleep apnoea [325]; multiple sclerosis [358]; myotonic dystrophy [260]; depression [96]; schizophrenia [370]; sleep deprivation [346]; and drug-induced sedation [485]. Modafinil has been found to enhance the activity of the dopaminergic system by increasing extracellular levels of dopamine [102, 298, 499] possibly by an action at the dopamine transporter [262, 310]. Consequently, it has been proposed that modafinil may potentiate LC activity via the enhancement of dopaminergic activity within the mesocoerulear pathway originating in the VTA [377, 383, 384]. It should be noted however, that modafinil failed to modify LC activity in anaesthetised animals [7] where the baseline firing rate of the neurones is very low. It has been suggested that this study should be repeated in awake animals where the LC fires at a higher rate and may be more sensitive to modafinil [383].

Modafinil’s pharmacological effects are consistent with those associated with increased LC activity (see 3.1 and Fig. (), above). Modafinil has been found to increase arousal in healthy volunteers [184, 187, 379, 488], together with signs of sympathetic activation, including increases in pupil diameter [184, 187, 379], heart rate and blood pressure [187, 264, 377, 379], and body temperature [283, 346]. Interestingly, there is little evidence of a concomitant decrease in parasympathetic activity, since light reflex amplitude and salivary output are not affected by the drug [184, 187, 377, 379]. This observation suggests that the mesocoerulear pathway may preferentially activate the pre-sympathetic neurones in the LC (see 5 and Fig. (), below).

Amisulpride is an antipsychotic with an antagonistic action at D2 dopamine receptors. D2 dopamine receptors have been shown to occur both pre-synaptically on dopaminergic neurones (autoreceptors) and post-synaptically: the pre-synaptic receptors inhibit the firing of the neurone [21], whereas the post-synaptic receptors may mediate either excitatory or inhibitory effects on the post-synaptic cell. The pre-synaptic receptors are generally more sensitive to both agonists and antagonists than the post-synaptic receptors, and amisulpride has a preferential action at the pre-synaptic autoreceptors [291, 337]. In this respect amisulpride differs from most other antipsycotics which although block D2 dopamine receptors [222, 432], do not show any selectivity for the pre-synaptic site [222, 291, 337]. In the case of the mesocoerulear pathway, the preferential blockade of inhibitory pre-synaptic receptors would increase the activity of the VTA neurones. As the dopamine released onto LC neurones is likely to interact with excitatory D2 dopamine receptors, the activity of the LC would increase leading to increase in alertness. Indeed, amisulpride has been shown to possess some mild alerting effects [331], in contrast to antipsychotics without pre-synaptic D2 dopamine receptor selectivity which have no alerting effect and are usually sedative in action [222].

Sedative Drugs

GABA Receptors

GABA is the major inhibitory neurotransmitter in the brain, and it exerts its action by interacting with three types of receptor (GABAA, GABAB, and GABAC). A major class of sedative drug, the benzodiazepines, interact with specific benzodiazepine receptors which are closely associated with the GABAA receptor. Activation of benzodiazepine receptors leads to potentiation of the inhibitory actions of GABA [289, 347]. As most sleep-promoting neurones utilise GABA as their neurotransmitter, benzodiazepines act by enhancing the influence of sleep-promoting systems.

It has been shown that benzodiazepines reduce the firing rate of LC neurones [239, 382, 410], and it has been proposed that the LC may play an important role in mediating the sedative effects of these drugs [240]. However, the reduction in LC activity after administration of benzodiazepines is unlikely to be due to potentiation of the inhibitory action of GABA on LC neurones since the GABAA receptors on these neurones are not sensitive to benzodiazepines [71]. Therefore, the suppression of LC activity by benzodiazepines is likely to reflect enhancement of GABAergic inhibition at other sites in the sleep-arousal network, e.g., in the cerebral cortex and TMN, structures with excitatory inputs to the LC (see 3.1.1 and 3.1.3.4, Part I). The benzodiazepine diazepam has been found to attenuate the stress-induced increases in noradrenaline turnover at sites such as the hypothalamus, amygdala, hippocampus and cerebral cortex [197], all areas which receive noradrenergic innervation originating in the LC. Interestingly, chronic diazepam administration enhances LC activity [338] and this over-activity may form part of the circuitry underlying benzodiazepine dependence and withdrawal.

It is generally recognised that there is a close relationship between the level of arousal and pupil diameter: sedation is known to be associated with miosis, as observed for the α2-adrenoceptor agonists and opiates (see 3.1, above), and pupil diameter is often used by anaesthetists to monitor the depth of anaesthesia (p 779-781 in ref. [254]). The anatomical substrate of this relationship is likely to be the LC (see 1.3, above). Therefore, it is surprising that the benzodiazepines, while highly sedative, do not cause any change in pupil diameter [186, 189], although they reduce LC activity (see above) and induce fluctuations in the firing rate of LC neurones as reflected in the enhancement of pupillary fatigue waves [189]. These observations suggest that the benzodiazepines, apart from reducing LC activity, may also have a direct effect on the pupil control mechanism which masks the miosis expected from the reduction in LC activity. This mechanism has been suggested to be enhanced sympathetically-mediated mydriasis resulting from reduced inhibition of the IML due to potentiation of GABA-mediated inhibition of descending inhibitory bulbospinal pathways and inhibitory interneurones [189].

Mesocoerulear Pathway

As discussed above, LC activity is influenced by a dopaminergic input from the VTA, the mesocoerulear pathway, operating via D2 dopamine receptors (see 3.2.1.2, above). Pre-synaptic autoreceptors play an important role in modulating the activity of VTA neurones, their activation leading to a decrease and their inhibition to an increase in neuronal activity. D2 dopamine receptor agonists, with a preferential affinity for the autoreceptor, lead to attenuation of the dopaminergic facilitation of LC activity resulting in lowering of the level of arousal [217, 373, 377, 378, 380]. Indeed, it has been shown that D2 dopamine receptor agonists used in the treatment of PD have profound sedative effects (for example, pramipexole [161]; ropinirole [116]; pergolide [463]; bromocriptine and cabergoline [333]; piribedil [452]: apomorphine [244]). These drugs are likely to exert their therapeutic effects via the activation of dopamine receptors within the striatum [217, 373].

Pramipexole is a dopamine D2 receptor agonist which has been shown to possess robust sedative effects in healthy volunteers [387, 388, 390]. However, paradoxically pramipexole-induced sedation was associated with an increase rather than a decrease in pupil diameter as would be expected on the basis of reduced LC activity. The increase in pupil diameter was accompanied by a reduction in light reflex amplitude, indicating a reduction in the parasympathetic outflow to the iris. It was proposed that the mydriatic effect of pramipexole might reflect the operation of a putative excitatory pathway from the VTA to the EWN (“meso-pupillomotor” pathway) whose “switching off” by autoreceptor stimulation would be responsible for the attenuation of parasympathetic activity [387, 388, 390]. Interestingly, this proposal is supported by the effect of the D2 autoreceptor antagonist amisulpride, which caused miosis and an increase in light reflex amplitude [388].

AGE-DEPENDENT ALTERATIONS OF LOCUS COERULEUS ACTIVITY

Neurone density within the LC decreases with age due to a progressive loss of noradrenergic neurones, both in animals [83, 246, 434] and humans [65, 265, 460, 477]. This neurone loss is uniformly diffuse across the LC, without preferential reduction in any restricted area [270]. In addition, the remaining neurones within the LC show shrinkage of the perikarya and a subsequent decrease in cell size [65, 83]. Ageing cells within the LC also exhibit mitochondrial and ribosomal alterations and these changes have been suggested to produce disruptions in the absorption of nutrients, protein synthesis, energy supply, transport of materials and message exchange [83]. The age-dependent decline in LC activity may be accentuated via an indirect mechanism. The ageing brain also shows a reduction in orexin B-immunoreactive axons within the LC accompanied by a decline in tyrosine hydroxylase mRNA in the LC, a marker of noradrenergic activity [105].

It has been observed that the number of LC neurones projecting to areas such as the frontal cortex and the hippocampus declines with age, but that a certain degree of axonal branching occurs to maintain noradrenaline levels at target areas [196, 197, 403]. However, despite this branching, the loss of noradrenergic LC axons innervating the frontal cortex has been found to result in fewer synapses [198], and changes in the electrophysiological properties of the remaining LC axon terminals have been observed [404]. Decreased binding in the LC of nisoxetine, a noradrenaline uptake inhibitor, has been observed in aged humans [456] and this decrease is likely to be related to the loss of LC neurones, and thus a reduction in noradrenaline transporters at nerve terminals. Similarly, in an aged rat nisoxetine-sensitive noradrenaline uptake inhibition was attenuated, again representing a decline in noradrenergic transporters at axon terminals [405]. In addition to a loss of transporters, α2-adrenoceptor responsiveness in the LC is reduced with ageing. In aged rats microinjections of clonidine and yohimbine into the LC, where these drugs have a localised effect on presynaptic inhibitory autoreceptors, do not modify alertness level, in contrast to the sedative and wakefulness-promoting effects, respectively, observed in younger rats [99, 312, 313]. Thus, these various disruptions in the functioning of the LC with age result in an overall deficiency in noradrenergic neurotransmission [34].

Memory impairment in old age has been related to the loss of LC function with ageing [272]. For example, reductions in cortical noradrenaline transmission with age have been associated with deficits in spatial learning and memory [78] and a significant correlation has been observed between the extent of neurone loss in the LC with age and the degree of memory impairment on an inhibitory avoidance task in mice [246].

This influence of ageing on LC activity can be observed in changes in pupillary function. Resting pupil diameter is reduced with age [37, 352, 416, 431], with pupil diameters of 1 mm or less becoming more prevalent [423], and this is consistent with a deficit in the sympathetic nervous system resulting from reduced LC activity. A decline in the sympathetic outflow to the iris in old age is further demonstrated by reductions in the amplitude and velocity of the darkness reflex response and prolongation of the recovery time of the light reflex response [37]. However, the parameters of the light reflex response may also be altered in old age [37, 352, 390, 431], suggesting that the aging process may affect both the sympathetic and parasympathetic controls of the pupil. The role of the LC in the age-related sympathetic deficit in pupillary control is highlighted by the fact that there is a parallelism between the monotonic decline in pupil size [416] and cell numbers in the LC [265] with age. The age-related decline in LC neurone numbers is likely to be accelerated in AD, resulting in accentuation of the sympathetic deficits of pupil control present in elderly people (see 5.2, below).

PATHOLOGICAL ALTERATIONS OF LOCUS COERULEUS ACTIVITY

Alongside the physiological and pharmacological manipulations that can produce changes in the activity of the LC, pathological changes associated with various diseases can alter LC neurone functioning. Pathological changes in the LC have been noted in a number of neurodegenerative diseases, including PD [514], AD [44], Huntington’s disease [521], progressive supranuclear palsy [266], Lewy body disease [435], Down’s syndrome [271], Pick’s disease [13], and amyotrophic lateral schlerosis [318]. In this review we focus our attention on the most common of these: PD and AD. In addition, the possible contribution of disruption to LC neurone function in brainstem coma is discussed.

Parkinson’s Disease

PD is a progressive neurodegenerative disorder associated with motor deficits that include muscular rigidity, bradykinesia, resting tremor, postural instability and hypokinesia. These deficits have been largely related to the degeneration of dopaminergic neurones in the pars compacta of the substantia nigra that project to the striatum, leading to a reduction in dopamine content within the striatum. However, there is evidence that the noradrenergic neurones of the LC are also important in this disorder [63, 136, 272]. A significant loss of LC neurones has been observed post-mortem in PD [32, 133, 332, 356, 472] and also indicated by a reduction in the neuromelanin signal localised to the LC using MRI in living patients ([386]; see 4.5, below). Indeed, neurone loss from the LC has been found to be more extensive than that from the substantia nigra [514], with Lewy body formation commencing in a number of areas including the LC before any pathology occurs in the substantia nigra [49, 97].

In addition to a loss of LC neurones, PD is also associated with morphological changes to the surviving neurones in the LC, including changes in the size and shape of both pre- and postsynaptic components of synapses, polymorphisms of the synaptic vesicles, changes in the morphology of the mitochondria, swelling of the cell bodies, inclusion of Lewy bodies, and shortening and thinning of the dendrites with absent or reduced arborisations [23, 64, 332].

It is known that the LC sends an excitatory noradrenergic projection to the striatum-projecting neurones of the substantia nigra [79, 146], activating the dopaminergic neurones via activation of α1-adrenoceptors [146]. Interestingly, lesions of the LC result in an increase in the loss of dopaminergic neurones from the substantia nigra induced by the neurotoxin 6-OHDA [35, 425], indicating that the noradrenergic neurones from the LC have a neuroprotective effect on the dopaminergic neurones of the substantia nigra. In addition, in monkeys with MPTP induced PD, lesions of the LC impair the recovery of the motor deficits that usually occurs at 9 weeks post-treatment [276], supporting the involvement of the LC in the progression of PD. It, therefore, seems likely that the noradrenergic neurones of the LC have both neuromodulatory effects on dopaminergic neurones of the substantia nigra, important for maintaining or facilitating the nigrostriatal pathway, and neuroprotective effects on these dopaminergic neurones, resulting in neurodegeneration when the LC is compromised and contributing to the development of PD [272, 424].

Sleepiness in PD has been found to be related to the pathology of the disease alongside any sedation induced by pharmacological treatment [14] and it is likely that this sleepiness results from the reduction in LC activity that occurs as a result of the neurone loss described above. In addition, the degree of LC neurone loss has been associated with the incidence of dementia in PD [520] and this association may be related to the loss of LC neurones involved in the circuitry underlying executive functioning (see Part I). In support of this suggestion, noradrenaline levels in the LC have been found to be reduced post-mortem in PD patients who also suffered from dementia compared to PD patients who had no clinical signs of dementia [60]. Alongside the sleepiness and dementia discussed above, depression and anxiety in PD may also be associated with the loss of LC neurones, resulting from a reduction in noradrenergic innervation of the limbic system [367].

Pharmacological studies suggest that α2-adrenoceptor antagonists could be used therapeutically in an attempt to increase LC neurone activity in PD. For example, in a primate model of PD administration of the α2-adrenoceptor antagonist idazoxan improved motor abnormalities [33]. This possibility requires further investigation.

Alzheimer’s Disease

AD is a progressive neurodegenerative disorder associated with a decline in cognitive functions including memory, language, attention, judgement and executive function (for example, planning and organisation). These deficits have primarily been related to dysfunction within the cholinergic system, particularly in the nucleus basalis. However, there is considerable evidence that dysfunction within the LC is also important in this disorder, since a significant loss of noradrenergic LC neurones can be observed post-mortem [58, 63, 64, 125, 133, 201, 259, 267, 272, 275, 433, 448, 472, 503]. This loss of LC neurones is greater than that observed in the case of normal ageing ([460]; see below) and interestingly there is significantly more neurone loss from the LC than from the cholinergic neurones in the nucleus basalis [267, 514]. It has been proposed that LC neurone degeneration may contribute to the development and progression of AD, since in amyloid-containing amyloid precursor protein 23 (APP23) transgenic mice, a model of AD pathology, LC lesions augmented amyloid plaque deposits in the projection areas of the LC and increased memory deficits compared to non-transgenic mice who also received LC lesions [172]. The root cause of the loss of neurones from the LC in AD is unclear, but may be associated with the formation of neurofibrillary tangles, since neurofibrillary tangles have been identified within the LC [58, 503]. In addition, increased levels of the neurotoxic monoamine oxidase A metabolite of noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, has been observed in the LC in AD and may contribute to this neurone loss [57]. It appears, however, that the LC neurone loss is not related to the over-expression of beta-amyloid protein [134].

Alongside the reduction in LC neurone density, mean brain noradrenaline concentration is lower in AD sufferers than in healthy controls [181] and cortical noradrenaline levels have been found to be reduced [201, 275]. In contrast, noradrenaline levels measured from the cerebro-spinal fluid are significantly higher in AD than in controls [110], and this may result from an increase in activity of some surviving neurones in order to compensate for the extensive neurodegeneration [181, 448]. Pathological changes are observable within these surviving LC neurones, however, where cell somata are reported as swollen and misshapen and dendrites are shorter and less branching [64].

The mechanism by which LC neurone loss contributes to AD development is unclear. In non-disease states noradrenaline from the LC may directly influence cell bodies of the nucleus basalis to increase acetylcholine release [272, 415, 509] and may modulate cortical cholinergic transmission via activation of α2-adrenoceptors on cholinergic terminals of cortically-projecting nucleus basalis neurones, again to increase acetylcholine release [170]. Therefore, a reduction in noradrenaline release from the LC in AD would result in a reduction in cholinergic neurotransmission. In addition, a loss of cholinergic innervation of the LC has been observed in AD [433] and this may contribute to the reduced LC functioning in AD discussed above.

As noradrenaline depletion studies using a neurotoxin to lesion the LC have found deficits in attention, learning and memory [272], neuronal loss in the LC may contribute to the cognitive decline in AD. It has been reported that as pathological changes in the LC occur early in AD, the early cognitive changes in the disorder may be related to LC degeneration [150]. LC degeneration is progressive during the course of the illness and there is a positive correlation between the duration of illness and the magnitude of LC neurone loss [133]. Furthermore, there are also positive correlations between the magnitude of LC neurone loss and dementia severity [44] and between the reduction in noradrenaline concentration in the cerebral cortex and cognitive impairment [275]. Interestingly, patients with a history of depression had significantly lower neurone numbers within the LC [125]. The LC may thus be a possible therapeutic target to alleviate the cognitive deficits in AD. It has been reported that transcutaneous electrical nerve stimulation (TENS), using the same stimulus parameters which have been shown to increase LC activity in experimental animals, results in improvements of both cognitive functions and behaviour in patients suffering from AD [389]. This observation opens the way to consider retrograde vagus nerve stimulation as a possible indication for AD, and indeed preliminary reports indicate that this procedure may have beneficial effects on cognitive functions in patients suffering from AD [285, 414]. The electrical stimulation of the left vagus nerve is well established as a therapeutic procedure both in epilepsy [149] and treatment-resistant depression [301]. Interestingly, it has been shown that vagus nerve stimulation leads to increases in the firing rates of noradrenergic neurones in the LC and serotonergic neurones in the dorsal raphe nucleus [103].

It may be expected that a reduction in LC activity, which is likely to occur from the earliest stages of AD, would be reflected in deficits in a number of LC-mediated functions. Indeed, there is evidence of a sympathetic deficit in AD patients, affecting sweat gland activity and pupillary function. A reduction in impulse traffic in sympathetic fibres innervating eccrine sweat glands results in hyposensitivity of the glands to intradermally injected carbachol ([443], see also 2.2.2), and it has been reported that patients suffering AD show reduced responsiveness of their sweat glands to carbachol, compared to age- and sex-matched control subjects [235]. It has also been reported that patients suffering from mild/moderate AD have reduced pupil diameters and attenuated darkness reflex responses in comparison to age matched healthy controls, indicating reduced sympathetic function, consistent with a reduction in LC activity [353].

Patients with AD may show enhanced sensitivity of their pupils to the mydriatic effect of topically applied tropicamide, a muscarinic cholinoceptor antagonist [391]. Although this observation has been related to degenerative changes in the EWN seen in AD [392], it is more likely to reflect the loss of LC activity. It has recently been found that administration of clonidine, a drug known to “switch off” LC activity (see 3.1.1), results in augmentation of tropicamide-evoked mydriasis in healthy volunteers [188]. This observation also suggests that administration of a single dose of clonidine is likely to enhance the sensitivity of the “tropicamide” eye-drop test in AD, providing possible means for the early detection of developing brain degeneration [188].

Reduction in LC activity in AD is also expected to be reflected in the level of alertness of AD patients. Indeed, it has been reported that patients suffering from AD have reduced flicker fusion frequency thresholds compared to age-matched healthy controls [87, 88], indicating a decline in the level of arousal, consistent with a reduction in LC activity in AD.

It has been reported that both saccadic [118, 183, 184, 191] and smooth pursuit [119, 191, 234, 510] eye movements are impaired in AD. Eye movements are controlled by an intricate neural network involving brainstem nuclei and the cerebral cortex and degenerative changes in several sites in this network may explain the eye movement deficiency reported in AD [372]. However, it is of interest that a reduction in LC activity may also contribute to the eye movement disorders. The LC sends an excitatory output to the oculomotor nuclear complex (see 2.3.5.4, Part I), and there is pharmacological evidence that drugs modifying LC activity lead to alterations in eye movements. Thus, α2-adrenoceptor agonists (dexmedetomidine, clonidine), which “switch off” the LC, reduce peak saccadic velocity in healthy volunteers [1, 139, 154], whilst α2-adrenoceptor antagonists (ethoxyidazoxan), which potentiate LC activity, increase peak saccadic velocity in healthy volunteers [81]. Furthermore, sedative drugs in general reduce peak saccadic velocity [24, 473], consistent with a reduction in LC activity evoked by these drugs.

Brainstem Coma

The presence of coma following brainstem stroke has been linked to lesions of nuclei located in the pons, in particular with the LC [330]. In this study, patients with brainstem damage without coma had no damage, or very little unilateral damage, to these areas in the tegmentum including the LC. Thus, lesions in the upper pons which include the LC are implicated in the causation of coma in humans, consistent with the wakefulness-promoting functions of this nucleus.

Imaging of Neuromelanin in Humans

The LC and the substantia nigra are visible to the naked eye when the brain is dissected since both nuclei contain a pigment, neuromelanin [515, 519]. It has recently become possible to image the substantia nigra [386] and the LC [386, 399, 400] see Fig. () using neuromelanin-magnetic resonance imaging. The contrast ratio between the neuromelanin-containing nuclei and the surrounding brain tissue is used as an index of neuromelanin concentration. Preliminary reports indicate that in PD the neuromelanin content is reduced both in the substantia nigra and the LC compared to healthy controls [386] and the neuromelanin content in the LC shows an inverted-U relationship with age, highest levels being observable in middle aged individuals [399]. Furthermore, a reduction in neuromelanin signal in the LC has been reported in patients suffering from depression [400]. These encouraging reports should be followed up by further work aimed at clarifying the relationship between neuromelanin content and cell numbers in the LC, since while the number of LC neurones has been reported to decline with age and the development of neurodegenerative diseases (see above), the neuromelanin concentration of pigmented nuclei seems to increase with the advancement of age [515]. Finally, the most important question is how neuromelanin content can be related to LC activity.

CONCLUSIONS

It is apparent that manipulations of a physiological, pharmacological or pathological nature produce consistent alterations in LC activity, affecting both arousal state and autonomic function. Clearly, the LC is a major nucleus in the central regulation of these functions and reliable outcomes from changes in LC activity can be observed, especially on pupillary measures. In general, the physiological manipulations discussed above (anxiety, noxious/painful stimulation, extreme ambient temperature) increase LC activity and thus result in heightened arousal and changes in autonomic function consistent with sympathetic activation (for example, pupil dilatation). Similarly, administration of drugs such as stimulants, α2-adrenoceptor antagonists and noradrenaline uptake inhibitors increase the influence of the LC on areas receiving noradrenergic innervation. In contrast, administration of sedatives and α2-adrenoceptor agonists reduce LC activity and result in a decrease in arousal and produce sympatholytic effects (for example, pupil constriction). Likewise, LC neurone loss in aging, PD, AD, and brainstem coma results in decreases in arousal and a reduction in activity of the sympathetic nervous system. It is of interest to note that the pathological changes within the LC that occur in PD and AD are similar in nature and thus these disorders may form two poles of a spectrum of neurodegenerative disease related to loss of LC neurones [272, 339]. Overall it is clear that the LC is centrally involved in controlling the regulation of arousal and autonomic function, and thus any manipulation (physiological, pharmacological or pathological) which alters LC activity will have consequences on aspects of this control.

The pattern of the consequences of LC activation by different variables suggests that there may be separate populations of LC neurones associated with sympatho-excitatory and parasympathetic-inhibitory effects (Fig. ()). Thus, noxious stimulation (see 2.1, above) and enhancement of the activity of the mesocoerulear pathway by the wakefulness-promoting drug modafinil (see 3.2.1, above) result in the relatively selective activation of pre-sympathetic LC neurones since these variables increase pupil diameter without any inhibition of the light reflex response. Indeed, modafinil has no influence on salivary output, a parasympathetically-mediated function. On the other hand anxiety (see 2.2, above), probably via activation of the amygdala, leads to preferential activation of pre-parasympathetic LC neurones leading to inhibition of the light reflex and reduction in salivation.

In conclusion, recent developments in the functional neuroanatomy of the central noradrenergic system have enabled the rational interpretation of the effects of a number of centrally-acting drugs. Conversely, many drugs have proved to be useful tools in the dissection of the complex neural network regulating arousal and autonomic activity. This fruitful relationship between functional neuroanatomy and pharmacological probes is likely to grow further with the development of neuroanatomical research tools of higher resolution and drugs with increasing selectivity and specificity.

Table 1

Effects of α2-Adrenoceptor Agonists on Central Noradrenergic Pathways

Pathway	α2-Adrenoceptors Activated		Effect on Pathway	Effect Mediated by Pathway	Net Effect
	Pre-	Post-
LC → VLPO	++	+	Inhibition ↓	Arousal ↓	Arousal ↓
LC → Cortex	++	0	Stimulation ↓	Arousal ↓
LC → EWN[1]	++	+	Inhibition ↓	Pupil Diameter ↓	Pupil Diameter ↓
LC → IML[1]	++	0	Stimulation ↓	Pupil Diameter ↓
LC → EWN[2]	+	++	Inhibition ↑	Pupil Diameter ↑	Pupil Diameter ↑
LC → IML[2]	++	0	Stimulation ↓	Pupil Diameter ↓
LC → RVLM	++	+++	Inhibition ↑	Blood Pressure ↓	Blood Pressure ↓
LC → IML	++	0	Stimulation ↓	Blood Pressure ↓
LC → Saliv. Nucl.	++	+++	Inhibition ↑	Salivation ↓	Salivation ↓

In man, dog and rabbit

In cat, rat and mouse

Abbreviations:

EWN    Edinger-Westphal nucleus

IML     intermediolateral cell column of the spinal cord

LC     locus coeruleus

RVLM   rostroventrolateral medulla

Saliv. Nucl. salivatory nuclei

VLPO    ventrolateral preoptic nucleus

Pre       pre-synaptic

Post     post-synaptic

Table 2

Effects of Noradrenaline Reuptake Inhibitors on Central Noradrenergic Pathways

Pathway	Effect on Pathway	Effect Mediated by Pathway	Net Effect
LC → VLPO	Inhibition ↑	Arousal ↑	Arousal ↑
LC → Cortex	Stimulation ↑	Arousal ↑
LC → EWN	Inhibition ↑	Pupil Diameter ↑	Pupil Diameter ↑
LC → IML	Stimulation ↑	Pupil Diameter ↑
LC → RVLM	Inhibition ↑	Blood Pressure ↓	Blood Pressure ↑ (minor change)
LC → IML	Stimulation ↑	Blood Pressure ↑
LC → Saliv. Nucl.	Inhibition ↑	Salivation ↓	Salivation ↓

Abbreviations:

EWN    Edinger-Westphal nucleus

IML      intermediolateral cell column of the spinal cord

LC        locus coeruleus

RVLM    rostroventrolateral medulla

Saliv. Nucl. salivatory nuclei

VLPO    ventrolateral preoptic nucleus

Table 3

Effects of α2-Adrenoceptor and µ-Opiate Receptor Agonists on Arousal and Pupil Diameter

		Arousal	Pupil Diameter
Pre-synaptic Action Dominant
Man	α2-adrenoceptor agonist	↓ [182]	↓ [39, 76, 184, 341, 379]
	µ-opiate receptor agonist	↓ [131]	↓ [225, 286, 334, 343, 344, 345]
Dog	α2-adrenoceptor agonist	↓ [84]	↓ [396]
	µ-opiate receptor agonist	↓ [502]	↓ [396]
Rabbit	α2-adrenoceptor agonist	no information available	↓ [8]
	µ-opiate receptor agonist	↓ [278]	↓ [450]
Post-synaptic Action Dominant
Cat	α2-adrenoceptor agonist	↑ [245]	↑ [231, 232]
	µ-opiate receptor agonist	↑ [95, 221]	↑ [80]
Rat	α2-adrenoceptor agonist	↑ [357]	↑ [137, 166, 169, 175, 231]
	µ-opiate receptor agonist	↑ [12, 484]	↑ [224]
Mouse	α2-adrenoceptor agonist	↑ [159]	↑ [167, 168]
	µ-opiate receptor agonist	↑ [215]	↑ [230]

References are indicated in square brackets.